Prima BioMed (IMMP) Stock Price, News & Analysis

Company Overview

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response. This candidate is being evaluated in multiple Phase II clinical trials across a range of solid tumors, including breast and lung cancers.

Founded in 2001 and headquartered in Sydney, Australia, Prima BioMed has built its expertise in immuno-oncology over two decades of research and development. In 2018, the company rebranded as Immutep to reflect its broader strategic focus on LAG-3–based immunotherapies. Since its inception, Prima BioMed has collaborated with leading academic institutions and cancer centers worldwide to advance its clinical programs and validate the therapeutic potential of LAG-3 modulation.

Prima BioMed maintains a global footprint with additional offices and research partnerships in Europe and the United States. Through collaborations with pharmaceutical partners and contract research organizations, the company aims to accelerate clinical development, streamline regulatory submissions and establish a foundation for potential commercialization. Its pipeline also includes monoclonal antibodies targeting LAG-3 and other immune checkpoints, underscoring a commitment to expanding treatment options for patients with hard-to-treat malignancies.

Key Stats

• Today's Range: $0.36 to $0.39
• 50-Day Range: $0.36 to $0.49
• 52-Week Range: $0.29 to $3.53
• Volume: 144,666 shs
• Average Volume: 6.56 million shs
• Market Capitalization: $56.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Hold

Prima BioMed Stock Analysis - MarketRank™

Prima BioMed scored higher than 59% of companies evaluated by MarketBeat, and ranked 378th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Prima BioMed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

Prima BioMed has a consensus price target of $5.50, representing about 1,339.8% upside from its current price of $0.38.

Amount of Analyst Coverage

Prima BioMed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Prima BioMed has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.51% of the float of Prima BioMed has been sold short.

Short Interest Ratio / Days to Cover

Prima BioMed has a short interest ratio ("days to cover") of 5.28.

Change versus previous month

Short interest in Prima BioMed has recently decreased by 44.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prima BioMed does not currently pay a dividend.

Dividend Growth

Prima BioMed does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

Prima BioMed has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Prima BioMed this week, compared to 4 articles on an average week.

MarketBeat Follows

1 people have added Prima BioMed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prima BioMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.07% of the stock of Prima BioMed is held by insiders.

Percentage Held by Institutions

2.32% of the stock of Prima BioMed is held by institutions.

Company Calendar

• Today: 8/03/2026
• Next Earnings (Estimated): 9/02/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMMP
• CIK: 1506184
• Web: www.immutep.com
• Phone: (128) 315-7003
• Fax: 61-2-8569-1880
• Employees: 2,021
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Prima BioMed: $5.50
• High Price Target: $10.00
• Low Price Target: $1.00
• Potential Upside/Downside: +1,340.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.97
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $6.69 million
• Price / Sales: 8.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.63 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 147,370,000
• Free Float: 142,848,000
• Market Cap: $56.27 million
• Optionable: Optionable
• Beta: 2.25